Dmitri Bobilev
Technik-/Wissenschafts-/F&E-Leiter bei FUSN PHAR
Vermögen: - $ am 30.04.2024
Aktive Positionen von Dmitri Bobilev
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
FUSN PHAR | Technik-/Wissenschafts-/F&E-Leiter | 07.11.2022 | - |
Karriereverlauf von Dmitri Bobilev
Ehemalige bekannte Positionen von Dmitri Bobilev
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.06.2018 | 01.08.2020 |
CHECKMATE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Ausbildung von Dmitri Bobilev
Omsk State Medical Academy | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 3 |
Kanada | 2 |
2 |
Operativ
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
FUSN PHAR | Health Technology |
Private Unternehmen | 2 |
---|---|
Vedanta Biosciences, Inc.
Vedanta Biosciences, Inc. BiotechnologyHealth Technology Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA. | Health Technology |
Checkmate Pharmaceuticals, Inc.
Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Dmitri Bobilev
- Erfahrung